Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks
The broad labeling that FDA approved for Benlysta, the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.
You may also be interested in...
The European Medicines Agency has recommended an impressive number of drugs for approval, including Merck & Co's hepatitis C therapy, Victrelis, Theravance's Vibativ and Amgen's Xgeva.
One week after receiving FDA approval for its breakthrough lupus drug, Human Genome Sciences is spending $50 million for broad rights to an early-stage cancer drug that hits a popular target.
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.